Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

British Journal of Cancer

Volumn 75, Issue 9, 1997, Pages 1360-1367

  Brain, E ^a,b   Garrino, C ^a   Misset, J L ^a   Garcia Carbonero, I ^a   Itzhaki, M ^a   Cvitkovic, E ^a   Goldschmidt, E ^a   Burki, F ^a   Regensberg, C ^a   Pappo, E ^a   Hagipantelli, R ^a   Musset, M ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Breast cancer; Primary chemotherapy; Prognostic factors

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PIRARUBICIN; VINDESINE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DATA ANALYSIS; FEMALE; FEVER; FOLLOW UP; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TREATMENT OUTCOME; VOMITING;

EID: 8244258025     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.230     Document Type: Article

References (36)

1. Beahrs OH, Henson DE, Hutter RVP and Kennedy BJ (eds) (1993) Manual for Staging of Cancer, 4th edn, pp. 161-167. JB Lippincott: Philadelphia, PA
2. Bonadonna G (1992) Evolving concepts in the systemic adjuvant therapy of breast cancer. Cancer Res. 52: 2127-2137
3. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans De Yoldi G, Zucali R, Rilke F, Amdreola S, Silvestrini R, Di Fronzo G and Valagussa P (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545
4. Briffod M, Spyratos F, Tubiana-Hulin M, Pallud C, Mayras C, Filleul A and Rouëssé J (1989) Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cancer 63: 631-637
5. Chevallier B, Mignot L, Delozier T, Morvan F, Ferme C and Herait P (1992) Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Am J Clin Oncol (CCT) 15: 395-398
6. Cox DR (1972) Regression models and life-tables. J R Stat Soc [B] 34: 187-220
7. De Lena M, Zucali R, Viganotti G, Valagussa P and Bonadonna G (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1: 53-59
8. De Maublanc MA (1991) Les données récentes de la cytoponction mammaire. Ann Pathol 11: 299-308
9. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 1-15, 71-84
10. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC and Blumenshein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578-2581
11. Fisher B and Mamounas EP (1995) Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537-540
12. Fisher B, Rockette H, Robidoux A, Margolese R, Cruz A, Hoehn J, Boysen D, Mamounas E, Wickerham DL and Decillis A (1994) Effect of preoperative therapy for breast cancer (BC) on local-regional disease: first report of NSABP B-18 (abstract 57). Proc Am Soc Clin Oncol 13: 65
13. Fletcher G (1972) Local results of irradiation in the primary management of localized breast cancer. Cancer 29: 545-551
14. Frye D, Buzdar A and Hortobagyi G (1995) Prognostic significance of axillary nodal involvement after preoperative chemotherapy in stage III breast cancer (abstract 81). Proc Am Soc Clin Oncol 14: 95
15. Henderson IC (1991) Prognostic factors. In Breast Diseases, 4th edn. Harris JR, Hellman S, Henderson IC and Kinne DW. (eds), pp. 332-346. JB Lippincott: Philadelphia, PA
16. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, McBride CM, Martin RG and Montague E (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507-2516
17. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, De Maublanc MA, Housset M, Forget G, Thill L, Soubrane C and Khayat D (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129
18. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Sta Assoc 53: 185, 1457-1481
19. Lin PP, Allison DC, Wainstock J, Miller KD, Dooley WC, Friedman N and Baker RR (1993) Impact of axillary lymph node dissection on the therapy of breast cancer. J Clin Oncol 11: 1536-1544
20. Maloisel F, Dufour P, Bergerat JP, Herbrecht R, Duclos B, Boilletol A, Giron C, Jaeck D, Haennel P, Jung G and Oberling F (1990) Results of initial doxorubicin, 5-fluorouracil and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 65: 851-855
21. Mansi JL, Smith IE, Walsh G, A'Hern RP, Harmer CL, Sinnett HD, Trott PA, Fisher C and McKinna JA (1989) Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 25: 1623-1627
22. Mantel N (1966) Evaluation of survival data and two row rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
23. Mauriac L, Durand M, Avril A and Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2: 347-354
24. Miller A, Hoogstraten B, Staquet M and Winkler P (1981) Reporting results of cancer treatment. Cancer 47: 207-214
25. Misset J-L, DI Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C and Mathe G (1996) Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after 16-year median follow-up duration. J Clin Oncol 14: 1136-1145
26. Ragaz J, Manji M, Plenderleith IH, Rebbeck P, Baird R, Basco V, Kuusk U, Olivotto I, McFarlane J, Clay G, Brown D, Worth A, O'Reilly S, Gelmon K, McGregor G, Spinelli J and Coldman A (1994) Impact of the residual disease in stage III breast cancer patients treated with preoperative (neoadjuvant) chemotherapy (CT), radiotherapy (XRT) and mastectomy. The 10 year analysis of the British Columbia study (abstract 88). Proc Am Soc Clin Oncol 13: 71
27. Rouëssé J, Friedman S, Sarrazin D, Mouriesse H, Le Chevalier T, Arriagada R, Spielmann M, Papacharalambous A and May-Levin F (1986) Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the institut Gustave-Roussy. J Clin Oncol 4: 1765-1771
28. Schaake-Koning C, van Der Linden EH, Hart G and Engelsman E (1985) Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiation Oncol Biol Phys 11: 1759-1763
29. Schnitt SJ, Connoly JL, Harris JR, Hellman S and Cohen RB (1984) Pathologic predictors of early recurrences in stage I and II breast cancer treated by primary radiation therapy. Cancer 53: 1049-1057
30. Schwanz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, Fellin FM and McFarlane J (1994) Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73: 362-369
31. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM and Chepic OF (1994) Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5: 591-595
32. Smith LE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna JA and Baum M (1995) High complete remission rates with primary neoadjuvant chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429
33. Swain SM, Sorace RA, Bagley CS, Danforth DN, Bader J, Wesley MN, Steinberg SM and Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer. Cancer Res 47: 3889-3894
34. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G and Veronesi U (1990) Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 15: 137-147
35. Van Der Wall E, Rutgers EJT, Holtkamp MJ, Baars JW, Schornagel JH, Peterse JL, Beijnen JH and Rodenhuis S (1996) Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Br J Cancer 73: 1080-1085
36. Zucali R, Uslenghi C, Kenda R and Bonadonna G (1976) Natural history and survival of inoperable breast cancer treated with radiotherapy followed by radical mastectomy. Cancer 37: 1422-1431